Sector
PharmaceuticalsOpen
₹5,152.25Prev. Close
₹5,177.05Turnover(Lac.)
₹225.85Day's High
₹5,249.55Day's Low
₹5,152.2552 Week's High
₹5,833.352 Week's Low
₹4,636.55Book Value
₹373.84Face Value
₹10Mkt Cap (₹ Cr.)
8,589.09P/E
38.02EPS
136.52Divi. Yield
5.0124 Aug 2023
12:00 AM
AGM
Announcement Date: 24 Aug, 2023
27 Sep 2024
12:00 AM
Board Meeting
Agenda : Audited Result
21 Aug 2024
12:00 AM
Dividend
Dividend Amount: 60
22 Aug 2024
12:00 AM
BookCloser
| Y/e 31 Mar( In .Cr) | Jun-2024 | Jun-2023 | Jun-2022 | Jun-2021 |
|---|---|---|---|---|
Equity Capital | 16.6 | 16.6 | 16.6 | 16.6 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 521.64 | 734.29 | 599.89 | 687.11 |
Net Worth | 538.24 | 750.89 | 616.49 | 703.71 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Jun-2021 | Jun-2020 | Dec-2017 | Dec-2016 |
|---|---|---|---|---|
Revenue | 1,008.73 | 1,355.86 | 1,103.96 | 992.56 |
yoy growth (%) | -25.6 | 22.81 | 11.22 | 5.64 |
Raw materials | -314.82 | -431.44 | -441.09 | -411.54 |
As % of sales | 31.2 | 31.82 | 39.95 | 41.46 |
Employee costs | -150.47 | -182.93 | -169.64 | -154.23 |
| Y/e 31 Mar( In .Cr) | Jun-2021 | Jun-2020 | Dec-2017 | Dec-2016 |
|---|---|---|---|---|
Profit before tax | 233.28 | 354.85 | 135.19 | 115.17 |
Depreciation | -30.04 | -29.45 | -26.4 | -24.81 |
Tax paid | -56.48 | -100.77 | -58.28 | -36.04 |
Working capital | -233.3 | 269.12 | 35.2 | 57.07 |
Other operating items |
| Y/e 31 Mar | Jun-2021 | Jun-2020 | Dec-2017 | Dec-2016 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -25.6 | 22.81 | 11.22 | 5.64 |
Op profit growth | -21.99 | 129.18 | 19.07 | 38.5 |
EBIT growth | -34.03 | 162.48 | 17.38 | 38.2 |
Net profit growth | -30.41 | 170.55 | 18.67 | 47.74 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,780.9 | 155.06 | 4,27,477.51 | 863.29 | 0.76 | 5,123.67 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,172.7 | 89.18 | 1,63,821.99 | 518 | 0.49 | 2,302 | 513.62 |
Cipla Ltd CIPLA | 1,533.9 | 29.27 | 1,23,920.06 | 1,178.16 | 0.85 | 3,969.86 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,324.2 | 68.82 | 1,12,592.36 | 460 | 0.84 | 2,376 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,561.2 | 51.21 | 1,02,659.66 | 634.43 | 0 | 2,529.74 | 269.23 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Independent Directo
S N Talwar
Independent Director
Rani A Jadhav
Managing Director
Milind Thatte
Non Executive Director
Aalok Agrawal
Company Sec. & Compli. Officer
Zeal Shah
Independent Director
S Madhavan
Executive Director
Lokesh Chandak
Non Executive Director
Seema Sambasivan
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Procter & Gamble Health Ltd
Summary
Procter & Gamble Health Limited (formerly Merck Limited), is an Indian-based company principally engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals. The company is the supplier of Pharmaceutical Chemicals, Formulated Chemical Products, Chemicals, Industrial Chemicals, Chemicals, Pharmaceutical Industry, and Chemical Products. The company offers prescription drugs, biotechnology products, and consumer health products, including over-the-counter products. They also offer products for the treatment of cancer, neurodegenerative diseases, infertility, endocrine and metabolic disorders, cardiovascular diseases, and other conditions with unmet medical needs.The company operates in two business divisions, namely Pharmaceuticals and Chemicals. The Pharmaceuticals business comprises of Ethicals used in the treatment of Cardiovascular and Metabolic diseases & Vitamin-based formulations and Consumer Health Care Products. The Chemicals business comprises of Bulk Drugs and Pigments. Segment revenue relating to the Chemicals business consists of bulk drugs, pigments and active pharmaceutical ingredients.Merck Ltd was incorporated in the year 1967 as E Merck (India) Ltd. The company was set up to take over the business of the Indian branch of Emeda Exports with all their assets and liabilities. The company is a 51% subsidiary of German firm Merck KGaA, is a leading player in vitamin formulations.The company started their operations as a manufacturer of ph
Read More
What is the Procter & Gamble Health Ltd share price today?
The Procter & Gamble Health Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹5174.15 today.
What is the Market Cap of Procter & Gamble Health Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Procter & Gamble Health Ltd is ₹8589.09 Cr. as of 02 Dec ‘24
What is the PE and PB ratio of Procter & Gamble Health Ltd?
The PE and PB ratios of Procter & Gamble Health Ltd is 38.02 and 16.01 as of 02 Dec ‘24
What is the 52 Week High and Low of Procter & Gamble Health Ltd?
The 52-week high/low is the highest and lowest price at which a Procter & Gamble Health Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Procter & Gamble Health Ltd is ₹4636.55 and ₹5833.3 as of 02 Dec ‘24
What is the CAGR of Procter & Gamble Health Ltd?
Procter & Gamble Health Ltd's CAGR for 5 Years at 3.61%, 3 Years at 1.44%, 1 Year at 0.43%, 6 Month at 8.15%, 3 Month at -0.59% and 1 Month at 3.27%.
What is the shareholding pattern of Procter & Gamble Health Ltd?
The shareholding pattern of Procter & Gamble Health Ltd is as follows:
Promoters - 51.82 %
Institutions - 21.45 %
Public - 26.74 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice
